MBC BioLabs is based in San Carlos, and Ridge Bio announced an oversubscribed $25 million seed round led by Sutter Hill Ventures in 2025.
Public source
Publisher name
Public post
Ridge Bio designs enzymes and targeted therapeutics that enable the next generation of precision medicines. The company’s labs are based at an MBC BioLabs in San Carlos,…
Company
MBC BioLabs
Where entrepreneurial scientists come to change the world.
- Industry
- Biotechnology Research
- Location
- San Francisco, US
- Company size
- 11–50 employees
About MBC BioLabs
MBC BioLabs believes startups are the greatest force for positive change in the world. We are dedicated to helping biotech startups succeed – we like to say that we enable awesome. We offer flexible and cost-effective lab space, complete with operational support and millions of dollars worth of state-of-the-art equipment and instrumentation, along with a vibrant community of like-minded individuals tackling the world's biggest problems. You pay only for what you need, and we handle all the logistics, maintenance, and upkeep so you can obsess about your science and business without distractions. We have helped launch and grow over 500 companies in our incubator since opening in October of 2013, and together, MBC companies have initiated 176 clinical trials, introduced 71 products to market, and collectively raised over $20 billion. MBC BioLabs has five sites: 953 Indiana St. and 135 Mississippi St, San Francisco, 733 Industrial Rd., and 930 Brittan Ave., San Carlos, and 1030 Brittan Ave., San Carlos.
See moreLatest activity
Latest activity from MBC BioLabs
3 signals
Partnerships
MBC BioLabs announced the 2026 EII Golden Ticket Competition alongside Eisai Innovation Inc to pursue early and research efforts in drug discovery technologies, novel targets, and biology for oncology and neurology.
Presence & Recognition
MBC BioLabs is hosting a morning of mass spectrometry innovation, practical workflows, and emerging applications on September 14th.
Discover more
Similar signals
Similar public activity from other companies.
Capital & Finance
Moonwalk Biosciences
Moonwalk Biosciences secured a $70 million Series B funding round directed at completing IND-enabling studies for its lead adipose-targeted siRNA candidate MW101 and taking it into first-in-human studies in late 2027.
Capital & Finance
BioCrowd
BioCrowd is funding $90 million into three science and technology centers for 5 years.
Capital & Finance
Camelot BioCapital
Camelot BioCapital reported eight deals up to $19 billion in CAR-T and in vivo CAR-T cell therapy, with zero of the eight showing a way to switch the cells off once they're in.
Capital & Finance
MassBio
MassBio raised a $33M seed round for F23 MassBioDrive alumni Cloverleaf Bio.
Capital & Finance
Ventac Studio